 SOUTH SAN FRANCISCO, Calif., Jan. 26, 2021 GLOBE NEWSWIRE -- Allogene Therapeutics, Inc. Nasdaq: ALLO, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T AlloCAR TTM therapies for cancer, today announced that Ton Schumacher, Ph.D., Principal Investigator at the Netherlands Cancer Institute and chair of Allogenes Scientific Advisory Board, has been awarded the 2021 Jeantet-Collen Prize for Translational Medicine. The award is presented every year by the Louis-Jeantet Foundation to distinguish leading-edge researchers in Europe, foster scientific excellence, and honor awardees conducting fundamental and translational research that is of considerable significance for medicine. 